107 related articles for article (PubMed ID: 11694776)
1. Photofrin II as an efficient radiosensitizing agent in an experimental tumor.
Schaffer M; Schaffer PM; Corti L; Sotti G; Hofstetter A; Jori G; Dühmke E
Onkologie; 2001 Oct; 24(5):482-5. PubMed ID: 11694776
[TBL] [Abstract][Full Text] [Related]
2. Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model.
Schaffer M; Schaffer PM; Corti L; Gardiman M; Sotti G; Hofstetter A; Jori G; Dühmke E
J Photochem Photobiol B; 2002 Apr; 66(3):157-64. PubMed ID: 11960724
[TBL] [Abstract][Full Text] [Related]
3. Photofrin as a radiosensitizer in an in vitro cell survival assay.
Kulka U; Schaffer M; Siefert A; Schaffer PM; Olsner A; Kasseb K; Hofstetter A; Dühmke E; Jori G
Biochem Biophys Res Commun; 2003 Nov; 311(1):98-103. PubMed ID: 14575700
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy combined with photofrin or 5-ALA: effect on Lewis sarcoma tumor lines implanted in mice. Preliminary results.
Schaffer M; Schaffer PM; Jori G; Corti L; Sotti G; Hofstetter A; Dühmke E
Tumori; 2002; 88(5):407-10. PubMed ID: 12487560
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy of photofrin II and excimer dye laser on experimental tumors.
Tanaka M; Uchibayashi T; Obata T; Sasaki T
Cancer Lett; 1995 Apr; 90(2):163-9. PubMed ID: 7736452
[TBL] [Abstract][Full Text] [Related]
6. The Application of Photofrin II as a sensitizing agent for ionizing radiation--a new approach in tumor therapy?
Schaffer M; Ertl-Wagner B; Schaffer PM; Kulka U; Jori G; Dühmke E; Hofstetter A
Curr Med Chem; 2005; 12(10):1209-15. PubMed ID: 15892632
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy of human bladder cancer cells in vitro correlated with cellular fluorescence levels of Photofrin-II.
Williams RD; Runge TC
Photochem Photobiol; 1987 Nov; 46(5):733-7. PubMed ID: 2964661
[No Abstract] [Full Text] [Related]
8. Increased efficacy of photodynamic therapy of R3230AC mammary adenocarcinoma by intratumoral injection of Photofrin II.
Gibson SL; van der Meid KR; Murant RS; Hilf R
Br J Cancer; 1990 Apr; 61(4):553-7. PubMed ID: 2139578
[TBL] [Abstract][Full Text] [Related]
9. Application of Photofrin II as a specific radiosensitising agent in patients with bladder cancer--a report of two cases.
Schaffer M; Schaffer PM; Vogesser M; Ertl-Wagner B; Rauch J; Oberneder R; Jori G; Hofstetter A; Dühmke E
Photochem Photobiol Sci; 2002 Sep; 1(9):686-9. PubMed ID: 12665306
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution of Photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: implications for photodynamic therapy.
Xiao Z; Miller GG; McCallum TJ; Brown KM; Lown JW; Tulip J; Moore RB
Photochem Photobiol; 1998 May; 67(5):573-83. PubMed ID: 9613241
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy of U87 human glioma in nude rat using liposome-delivered photofrin.
Jiang F; Lilge L; Grenier J; Li Y; Wilson MD; Chopp M
Lasers Surg Med; 1998; 22(2):74-80. PubMed ID: 9484699
[TBL] [Abstract][Full Text] [Related]
12. The effect of photodynamic therapy on a retinoblastoma-like tumour. An experimental in vitro and in vivo study on the potential use of photodynamic therapy in the treatment of retinoblastoma.
Winther JB
Acta Ophthalmol Suppl (1985); 1990; (197):1-37. PubMed ID: 2176429
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience.
Nseyo UO; DeHaven J; Dougherty TJ; Potter WR; Merrill DL; Lundahl SL; Lamm DL
J Clin Laser Med Surg; 1998 Feb; 16(1):61-8. PubMed ID: 9728133
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy of human malignant melanoma xenografts in athymic nude mice.
Nelson JS; McCullough JL; Berns MW
J Natl Cancer Inst; 1988 Mar; 80(1):56-60. PubMed ID: 2963136
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy of human squamous cell carcinoma in vitro and in xenografts in nude mice.
Megerian CA; Zaidi SI; Sprecher RC; Setrakian S; Stepnick DW; Oleinick NL; Mukhtar H
Laryngoscope; 1993 Sep; 103(9):967-75. PubMed ID: 8361317
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance to photofrin-mediated photodynamic therapy and UV light and recovery from photodynamic therapy damage in Rif-8A mouse fibrosarcoma cells measured using viral capacity.
DiProspero L; Singh G; Wilson BC; Rainbow AJ
J Photochem Photobiol B; 1997 Apr; 38(2-3):143-51. PubMed ID: 9203375
[TBL] [Abstract][Full Text] [Related]
17. Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor.
Peng Q; Moan J; Kongshaug M; Evensen JF; Anholt H; Rimington C
Int J Cancer; 1991 May; 48(2):258-64. PubMed ID: 1826901
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy in the management of bladder cancer.
Nseyo UO
J Clin Laser Med Surg; 1996 Oct; 14(5):271-80. PubMed ID: 9612193
[TBL] [Abstract][Full Text] [Related]
19. Development of an HPLC method for monitoring of Photofrin II therapy.
Vogeser M; Schaffer M; Egeler E; Spöhrer U
Clin Biochem; 2005 Jan; 38(1):73-8. PubMed ID: 15607320
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of photofrin II as a radiosensitizing agent in solid tumors--preliminary results.
Schaffer M; Ertl-Wagner B; Schaffer PM; Kulka U; Jori G; Wilkowski R; Hofstetter A; Dühmke E
Onkologie; 2006 Nov; 29(11):514-9. PubMed ID: 17068386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
